#PortfolioNews I Our portfolio company #Minoryx Therapeutics has dosed the first patient in the Phase 2a TREE study of #leriglitazone for #RettSyndrome! 🧠

🗓️ Results expected in H12026
👉 buff.ly/NycHUxI

#CNS #RareDisease #vc